Magazine

Cancer biological therapy market to reach around us$ 2 9 billion by 2021

Description
Report Information More information from: https://www.marketresearchfuture.com/reports/616Cancer Biological Therapy Market Research Report- EMEA Forecast To 2021…
Categories
Published
of 9
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Transcript
Report Information More information from: https://www.marketresearchfuture.com/reports/616Cancer Biological Therapy Market Research Report- EMEA Forecast To 2021 Report / Search Code: MRFR/HC/0173-CRRPriceDescription:1-user PDF : $ 4450.0Publish Date: 14 April, 2017Enterprise PDF : $ 6250.0Cancer Biological Therapy market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2021 Market Synopsis of Cancer Biological Therapy Market: Market Scenario: Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. At the molecular level, cancer is a genetic disease that develops due to mutation of genes in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Metastasis of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. Lots of research has been performed to understand cellular and molecular genetic changes and the host-tumor interactions which is responsible for tumor development and progression. It was found that; molecular oncology helped to understand cancer pathogenesis and drug action, as well as helped to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. The EMEA market for Cancer Biological Therapy is growing steadily and has a bright future. In EMEA the market for Cancer Biological Therapy is expected to grow at the rate of about XX% from 2016 to 2021.Study objectives of Cancer Biological Therapy Market: To provide detailed analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Cancer Biological Therapy market To provide insights about factors affecting the market growth To analyze the market based on various factors-price analysis, supply chain analysis, porters five force analysis etc. To provide historical and forecast revenue of the market segments and sub-segments with respect to two main geographies and their countriesEurope and Middle East & Africa. To provide country level analysis of the market with respect to the current market size and future prospective To provide country level analysis of the market for segments by type, by end user and its subsegments. To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the EMEA Cancer Biological Therapy market. Cancer Biological Therapy Market, by RegionIntended Audience Cancer Biological Therapy devices manufacturers and suppliers Biotechnology Companies Research and Development (R&D) Companies Government Research Laboratories Government and Independent Regulatory Authorities Medical Research InstitutesKey Findings The Cancer Biological Therapy EMEA market and is expected to reach $29,776.3 million by 2021. Interferon’s segment holds the largest share in the market. Europe holds the largest market share of 77.2% of Cancer Biological Therapy market and is anticipated to reach $23,248.3 million by the end of forecast period. Monoclonal Antibodies is expected to be fastest growing segment and are anticipated to grow at the rate of 4% during the forecast period.Segments: Cancer Biological Therapy market has been segmented on the basis of types which comprises of monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others. On the basis of end user, market is segmented into hospitals & clinics, cancer research centers, laboratories and others.Regional Analysis of Cancer Biological Therapy Market: Europe commands the largest market of EMEA Cancer biological therapies and is expected to reach $ 23,248.3 million by 2021. The European market for cancer biological therapies is expected to grow at a CAGR of 5.2%% by the end of the forecasted period The Middle East cancer biological therapy market is majorly divided into; Qatar, UAE, Kuwait, Bahrain, Oman, Saudi Arabia, and rest of Middle East. The market for Middle East is expected to reach $ 6528.0 million by 2021 which is expected to grow at a CAGR of 4.3%.Key Players for Cancer Biological Therapy Market Some of the key players in this market are:, Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, Eli Lilly And Company, Engeneic Ltd, f. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis, Pfizer Inc., Seattle Genetics, Inc., Teva Pharmaceutical Industries Ltd and Others. The report for Cancer Biological Therapy market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regionsContents:Table Of Contents 1 Report Prologue2INTRODUCTION 2.1definition2.2Scope of Study:2.2.1 2.3 3MARKET STRUCTURE Research Process:3.1Primary Research:3.2Secondary Research:3.3top-down & bottom-up approach:4MARKET DYNAMICS 4.1DRIVERS4.1.1Increasing Cancer Survival Rate4.1.2Growing demand for advanced therapies4.1.3Less number of side effects as compared to conventional treatment methods4.1.4Growth of cancer healthcare facilities in emerging countries4.1.5chainging lifestyle and increasing smoking population in middle east & africa4.2RESTRAINTS4.2.1 4.34.4 5High cost of Cancer biological therapy Opportunities4.3.1UnTapped types of CancersMACROECONOMIC INDICATORS EMEA Cancer biological therapy, by phases5.1Introduction5.2Phases67Research ObjectiveEMEA Cancer Biological Therapy Market, BY Type 6.1key findings6.2Monoclonal Antibodies6.3Interferons6.4Interleukins6.5Cancer growth inhibitors6.6Gene Therapy6.7Colony-Stimulating Factors6.8Targeted Therapy6.9CANCER VACCINES EMEA Cancer Biological Therapy market, by end-users167.1key findings7.2Introduction7.3Hospitals & Clinics7.4Cancer Research Centers7.5Laboratories8EMEA Cancer Biological Therapy, by Region 8.1key findings8.2Europe8.3Middle East & Africa9Competitive landscape 9.11031Market Share Analysis EMEA Cancer Biological Therapy Market, By Company10.1Amgen Inc.10.1.1Overview10.1.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.1.3FINANCIAL UPDATES10.1.4KEY DEVELOPMENTS10.2Bristol-Myers Squibb10.2.1Overview10.2.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.2.3FINANCIAL UPDATES10.2.4KEY DEVELOPMENTS10.3Celgene Corporation10.3.1Overview10.3.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.3.3FINANCIAL UPDATES10.3.4KEY DEVELOPMENTS10.4ELI Lilly and Company10.4.1Overview10.4.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.4.3FINANCIAL UPDATES10.4.4KEY DEVELOPMENTS10.5EnGeneIC Ltd10.5.1Overview10.5.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.5.3Financials UPDATES10.5.4 10.6Key Developments F. Hoffmann-La Roche AG10.6.1Overview10.6.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.6.3FINANCIAL UPDATES10.6.4KEY DEVELOPMENTS10.7Merck & Co., Inc.10.7.1Overview10.7.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.7.3FINANCIAL UPDATES10.7.4KEY DEVELOPMENTS10.8Novartis10.8.1Overview10.8.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.8.3FINANCIAL UPDATES10.8.4KEY DEVELOPMENTS10.9pfizer Inc.10.9.1Overview10.9.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.9.3FINANCIAL UPDATES10.9.4KEY DEVELOPMENTS10.10Seattle Genetics, Inc.10.10.1Overview10.10.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.10.3FINANCIAL UPDATES10.10.4key developments10.11Teva Pharmaceutical Industries Ltd10.11.1Overview10.11.2PRODUCT/BUSINESS SEGMENT OVERVIEW10.11.3Financials10.11.4Key Developments  List of Tables TABLE 1 EMEA cancer biological therapy market, by type, 2013-2021 (USD million) TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER Biological THERAPY MARKET, BY REGION, 2013-2021 (USD million)TABLE 3 INTERFERONS FOR CANCER Biological THERAPY MARKET, BY REGION 20132021 (USD MILLION) TABLE 4 INTERLEUKINS FOR CANCER Biological THERAPY MARKET, BY REGION 20132021 (USD MILLION) TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2013-2021 (USD MILLION) TABLE 6 GENE THERAPY FOR CANCER Biological THERAPY MARKET, BY region 2013-2021 (USD MILLION) TABLE 8 TARGETED DRUG DELIVERY FOR CANCER Biological THERAPY MARKET, BY REGION 2013-2021 (USD MILLION) TABLE 9 CANCER VACCINES FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2013-2021 (USD MILLION) TABLE 10Emea cancer biological therapy market, by end-users 2013-2021 (USD MILLION)TABLE 11 MILLION)EMEA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2013-2021 (USDTABLE 16 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END-UESRS, 2013-2021 (USD MILLION) TABLE 18 MILLION)U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END-UESRS, 2013-2021 (USDTABLE 19 MILLION)ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USDTABLE 25 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY, 20132021, (USD million) TABLE 30 Gulf Cooperation Council (GCC) CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD million) TABLE 31 Gulf Cooperation Council (GCC)CANCER BIOLOGICAL THERAPY MARKET,BY ENDUESRS, 2013-2021 (USD million) TABLE 32Qatar CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usd million)TABLE 33 million)Qatar CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USDTABLE 34UAE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usd million)TABLE 35 million)UAE CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USDTABLE 36 million)Kuwait CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usdTABLE 37 Kuwait CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD million) TABLE 38 million)Bahrain CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usdTABLE 39 Bahrain CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD million) TABLE 40 million)Oman CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usdTABLE 41 million)Oman CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USDTABLE 42 million)Saudi Arabia CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USDTABLE 43 Saudi Arabia CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 20132021 (USD million) TABLE 44 rest of middle east CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (USD million) TABLE 45 rest of middle east CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 20132021 (USD million) TABLE 46Africa CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2013-2021 (usd million)TABLE 47 million)Africa CANCER BIOLOGICAL THERAPY MARKET,BY END-UESRS, 2013-2021 (USD  List of Figures FIGURE 1 Research Process FIGURE 2top-down & bottom-up approach:FIGURE 3MARKET DYNAMICS for EMEA cancer biological therapy marketFIGURE 4Attrition Rate of Phase III Clinical Trials in Europe, 2012 (%)FIGURE 5Cancer biological therapy success rates in various phases of clinical trialsFIGURE 6EMEA cancer biological therapy market, by typeFIGURE 7Monoclonal antibodies market, by type, 2015 (usd million)FIGURE 8interferons market, by type, 2015 (usd million)FIGURE 9Emea cancer biological therapy market, by end-usersFIGURE 10EMEA CANCER BIOLOGICAL THERAPY MARKET, BY REGIONFIGURE 11Europe cancer biological therapy market, by country, 2015 (%)FIGURE 12Europe cancer biological therapy market, by type, 2015 (usd million)FIGURE 13Europe Cancer biological therapy by types, 2013-2021 (usd million)FIGURE 14Europe cancer biological therapy market, by type, 2015 (usd million)FIGURE 15Middle east cancer biological therapy market, by country, 2015 (usd million)FIGURE 16Qatar: Cancer incidence and mortality rates (%)FIGURE 17UAE: Cancer incidence and mortality rates (%)FIGURE 18Kuwait: Cancer incidence and mortality rates (%)FIGURE 19Bahrain: Cancer incidence and mortality rates (%)FIGURE 20Oman: Cancer incidence and mortality rates (%)FIGURE 21Saudi Arabia: Cancer incidence and mortality rates (%)FIGURE 22Middle east cancer biological therapy market, by type, 2015 (usd million)FIGURE 23Middle east cancer biological therapy market, by end-users, 2015 (usd million)FIGURE 24Africa cancer biological therapy market, by type, 2015 (usd million)FIGURE 25Africa cancer biological therapy market, by type, 2015 (usd million)FIGURE 26EMEA Cancer Biological Therapy Market: company Share Analysis, 2015 (%)marketresearchfuture.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349
Search
Related Search
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks